Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AcelRx Names New CEO

This article was originally published in Scrip

Executive Summary

AcelRx Pharmaceuticals Inc. has appointed Howard B. Rosen CEO after he served as interim CEO for the company – effective April 1, 2016. Rosen previously held senior-level general management positions and functional roles at Gilead Sciences Inc. and ALZA Corp. Most recently he was interim CEO of Pearl Therapeutics (acquired by AstraZeneca) and has served on AcelRx's board of directors since 2008. Rosen is also on the board for Alcobra Ltd.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst